Navigation Links
3-V Biosciences Completes $20 Million Series C Financing
Date:6/21/2013

MENLO PARK, Calif., June 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V's lead oncology candidate into a Phase 1 clinical trial and to conduct ongoing preclinical studies of multiple virology leads generated by the company's integrated drug discovery process. Existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates participated in the round.

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"I am very pleased by the recognition of our efforts and continued support from our existing investors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences. "3-V takes an integrated approach to building its pipeline by applying our proprietary screening methodology combined with our expertise in medicinal chemistry, drug discovery and development to generate proprietary therapeutic candidates that target key pathways in oncology and infectious diseases. Our lead oncology candidate has demonstrated compelling anti-tumor activity in pre-IND studies and with the funds from our Series C, we look forward to advancing into the clinic later this year."

3-V's lead molecule is one of a series of novel fatty acid synthase (FASN) inhibitors initially being developed to treat solid tumor cancers. FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V has demonstrated potent activity against multiple tumor types, including lung, breast, prostate and colon cancers. In addition, 3-V has demonstrated potential synergy of its FASN-inhibitors with cytotoxic agents. 3-V plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the third quarter and initiate first-in-human studies by the end of 2013.

"The team at 3-V has done an impressive job of generating a pipeline of novel therapeutic product candidates with promising activity in diverse oncology and infectious disease indications," said David Mott, General Partner of New Enterprise Associates and Chairman of the Board of 3-V Biosciences. "We are pleased to support 3-V's continued efforts as they advance their lead program into clinical development."

3-V is leveraging its screening platform, drug discovery and drug development capabilities to identify antiviral candidates that exploit the dependence of the virus on the host cell by blocking host-virus interactions. The leads in the company's pipeline are characterized by their novel mechanism of action, broad-spectrum antiviral activity and high barrier to resistance. 3-V is currently evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV).

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com


'/>"/>
SOURCE 3-V Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... ...
(Date:1/13/2017)... , January 13, 2017 ... "Transfection Reagents and Equipment Market by Method (Biochemical ... Application (Biomedical, Protein Production), End User - Global ... studies the global market from 2016 to 2021. ... Billion by 2021 from USD 715.4 Million in ...
(Date:1/13/2017)... , January 13, 2017 The 2016 ... industry, with several states voting in favor of legalizing cannabis ... largest Cannabis market in the U.S. In addition, the state ... mark in annual cannabis products sales. The ArcView Group has ... which the legal cannabis sales in the U.S. last year ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
(Date:1/16/2017)... UT (PRWEB) , ... January 16, 2017 , ... One ... not only to treat, but to test for, as well. The money spent screening ... every year.(1) Doctors in the U.S. screen patients for cancer more than in any ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Executive Officer of the medical device company, effective immediately. , “This is perfect ... “Kevin has a strong track record in medical device market development and revenue ...
(Date:1/15/2017)... ... , ... In this role, Courtney will be responsible for developing new business ... friendly mark. This certification program was created by ASL and the nonprofit Asthma and ... suitable for the 60+ million people living in the U.S. with asthma and allergies. ...
(Date:1/15/2017)... ... ... is announcing the release of an updated version of their top selling clipper, the ... wide jaws that will accommodate nails up to 4mm in thickness . Nails like ... reinforced for extra strength when pressing down on dense nails which can be a hindrance ...
Breaking Medicine News(10 mins):